title: [Screening for markers of blood-borne diseases in donated units collected in France from 1993 to 1995].
abstract: A decrease of positive donation rates for antibodies to HIV, to HCV and for HBs Ag has been observed between 1993 and 1995 both in first-time and regular donations. In first-time donors, the most important decrease has been observed for HIV and in regular donors for HCV and HBs Ag. The interval between the negative and the positive donations was inferior to 1 year for 50% of regular donors and was superior to 2 years for 20 to 30%. About 30% of HIV positive donations were positive for other markers: 23% for anti-HBc and 10% for anti-HCV. About 40% of HCV positive donations had an elevated ALT level. Risk factors related to HIV heterosexual transmission appear to be the most difficult to identify during the donor selection and the least often associated with other markers. In recently HCV-infected donors, the main risk factors were IV drug addiction (25%) and nosocomial infection (30%). The major HTLV risk factor was directly or indirectly linked to the Caribbean area. Important differences between continental France and overseas territories were observed for HIV and HBs Ag rates.
authors.affiliation: Agence Française du Sang, Paris.
authors.forename: C
authors.initials: C
authors.lastname: Saura
authors.forename: J
authors.initials: J
authors.lastname: Pillonel
authors.forename: A M
authors.initials: AM
authors.lastname: Couroucé
mesh_terms: D015492:AIDS Serodiagnosis; D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D015415:Biomarkers; D001782:Blood Donors; D003140:Communicable Disease Control / Q000379:methods* / Q000706:statistics & numerical data; D015480:Deltaretrovirus Antibodies / Q000097:blood; D006800:Deltaretrovirus Infections / Q000097:blood / Q000453:epidemiology / Q000517:prevention & control; D005260:Female; D005602:France / Q000453:epidemiology; D015483:HIV Antibodies / Q000097:blood; D015658:HIV Infections / Q000097:blood / Q000453:epidemiology / Q000517:prevention & control; D006679:HIV Seropositivity / Q000453:epidemiology; D006509:Hepatitis B / Q000097:blood / Q000453:epidemiology / Q000517:prevention & control; D006514:Hepatitis B Surface Antigens / Q000097:blood; D006526:Hepatitis C / Q000097:blood / Q000453:epidemiology / Q000517:prevention & control; D018937:Hepatitis C Antibodies / Q000097:blood; D006801:Humans; D008297:Male; D008403:Mass Screening; D012189:Retrospective Studies; D012307:Risk Factors; D016036:Seroepidemiologic Studies; D012725:Sexual Behavior / Q000706:statistics & numerical data; D015819:Substance Abuse, Intravenous / Q000453:epidemiology; D013587:Syphilis / Q000097:blood / Q000453:epidemiology / Q000517:prevention & control; D013588:Syphilis Serodiagnosis; D014777:Virus Diseases / Q000097:blood / Q000453:epidemiology / Q000517:prevention & control* / Q000635:transmission
chemical_list: D015415:Biomarkers; D015480:Deltaretrovirus Antibodies; D015483:HIV Antibodies; D006514:Hepatitis B Surface Antigens; D018937:Hepatitis C Antibodies; D000410:Alanine Transaminase